![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1368649
¸ðÀ¯ ¿Ã¸®°í´ç(HMO) ½ÃÀå ±Ô¸ð : ³óµµº°, ¿ëµµº°, ¼¼°è ¿¹Ãø(2023-2032³â)Human Milk Oligosaccharides (HMO) Market Size - By Concentration (Neutral HMO, Acidic HMO), By Application (Infant Formula, Dietary Supplements, Food and Beverage) & Global Forecast, 2023 - 2032 |
¼¼°èÀÇ ¸ðÀ¯ ¿Ã¸®°í´ç(HMO) ½ÃÀåÀº 2023-2032³â 22.5%ÀÇ CAGR·Î ¼ºÀåÇÕ´Ï´Ù.
À¯¾ÆÀÇ ¸é¿ªÃ¼°è ¹ß´Þ°ú Àå °Ç°¿¡¼ÀÇ ¿ªÇÒ°ú °°Àº ÀÎüÀ¯·¡ ¿Ã¸®°í´ç(HMOs)ÀÇ °Ç°»óÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼ »ê¾÷ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀÔ´Ï´Ù.
¶ÇÇÑ À¯´çºÒ³»Áõ À¯º´·ü Áõ°¡¿Í À¯¾ÆÀÇ ¸ðÀ¯ ¼öÀ¯·ÎÀÇ ÀüȯÀº ¸ðÀ¯ ¿Ã¸®°í´ç(HMO) ±â¹Ý ºÐÀ¯ ÆÇ¸Å¸¦ Áõ°¡½Ãų °ÍÀ̸ç, MedlinePlusÀÇ ÃßÁ¤¿¡ µû¸£¸é Àα¸ÀÇ ¾à 65%°¡ À¯¾Æ±â¿¡ À¯´çÀ» ¼ÒÈÇÏ´Â ´É·ÂÀÌ ÀúÇϵǾî ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¼ºÀÎ ¿µ¾çÇÐ ¹× ÀǾàǰ°ú °°Àº ºÐ¾ß¿¡¼ Àΰ£ ¸ðÀ¯ ¿Ã¸®°í´ç(HMO)ÀÇ ÀáÀçÀû ÀÀ¿ë¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ¿¬±¸´Â ºñÁî´Ï½º ¼ºÀåÀÇ »õ·Î¿î ±âȸ¸¦ âÃâÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.
¸ðÀ¯ ¿Ã¸®°í´ç Á¦Á¶¾÷ü¿Í À¯¾Æ¿ë Á¶Á¦ºÐÀ¯ Á¦Á¶¾÷ü°£ÀÇ Á¦ÈÞ ¹× Çù·Â °ü°è Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» ´õ¿í È®´ëÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀåÀº À¯¾Æ¿ë ¿µ¾ç Á¦Ç°¿¡ ¸ðÀ¯ ¿Ã¸®°í´ç(HMO)À» ÷°¡ÇÏ´Â °Í¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ ÁöÁö°¡ Áö¼ÓÀûÀ¸·Î ¹ßÀüÇÔ¿¡ µû¶ó º¸¿ÏµÉ °ÍÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Çù·Â °ü°è¿Í ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀº ¾÷°è ¼ºÀåÀ» °¡¼ÓÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ»ÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.
½ÃÀåÀº ³óµµ, ¿ëµµ ¹× Áö¿ª¿¡ µû¶ó ºÐ·ùµË´Ï´Ù.
³óµµ ±âÁØÀ¸·Î »ê¼º HMO ºÎ¹®Àº 2032³â±îÁö »ó´çÇÑ CAGRÀ» ¹Ý¿µÇÒ °ÍÀÔ´Ï´Ù. »ê¼º HMOÀÇ °Ç°»óÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í, Ư¼ö À¯¾Æ ¿µ¾ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϸç, À¯¾Æ °Ç°¿¡ ´ëÇÑ ÀÌÁ¡À» ÀÔÁõÇÏ´Â Áö¼ÓÀûÀÎ ¿¬±¸°¡ ÁøÇàµÇ¸é¼ ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀÔ´Ï´Ù.
¿µ¾ç º¸ÃæÁ¦ ¿ëµµ´Â 2032³â±îÁö ¸ðÀ¯ ¿Ã¸®°í´ç(HMO) ½ÃÀå¿¡¼ ÁÖ¸ñÇÒ ¸¸ÇÑ Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, HMOÀÇ ÀáÀçÀûÀÎ °Ç°»óÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ¼ÒºñÀÚÀÇ ÀνÄÀÌ ³ô¾ÆÁö°í, ÀÔÁõµÈ ÇÁ¸®¹ÙÀÌ¿Àƽ½º Ư¼º, ±â´É¼º ¹× ¿µ¾ç º¸ÃæÁ¦, ƯÈ÷ Àå °Ç° ¹× ¸é¿ª·Â °È¿¡ ÃÊÁ¡À» ¸ÂÃá ±â´É¼º ¹× ¿µ¾ç º¸ÃæÁ¦¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.
Áö¿ªÀûÀ¸·Î ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¸ðÀ¯ ¿Ã¸®°í´ç(HMO) ½ÃÀåÀº Ãâ»êÀ² Áõ°¡, °¡Ã³ºÐ ¼Òµæ Áõ°¡, ¿µ¾Æ ¿µ¾ç¿¡ ´ëÇÑ Á߿伺 Áõ°¡ µîÀÇ ¿äÀο¡ ÈûÀÔ¾î ºÐ¼® ±â°£ Áß ÄªÂùÇÒ ¸¸ÇÑ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ¶ÇÇÑ ¸ðÀ¯ ¼öÀ¯ÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í °í±Þ À¯¾Æ¿ë Á¶Á¦ ºÐÀ¯ Á¦Ç°ÀÇ Ã¤ÅÃÀº Áö¿ª »ê¾÷ÀÇ ¼ºÀåÀ» ´õ¿í ÃËÁøÇÒ °ÍÀÔ´Ï´Ù.
The global human milk oligosaccharides market will grow at a 22.5% CAGR from 2023 to 2032. The increasing awareness of the health benefits of human milk oligosaccharides (HMOs) such as their role in infant immune system development and gut health, will fuel industry growth.
Additionally, the rising prevalence of lactose intolerance and the shift towards breastfeeding alternatives for infants will boost human milk oligosaccharides-based formula sales. According to estimates from MedlinePlus, close to 65% of the human population experiences a decline in the ability to digest lactose post-infancy. Furthermore, ongoing research into potential applications of human milk oligosaccharides in areas like adult nutrition and pharmaceuticals will create new opportunities for business growth.
The increasing partnerships and collaborations between manufacturers of human milk oligosaccharides and producers of infant formula will further augment market growth. This growth will be complemented by the ongoing evolution of regulatory support for the inclusion of human milk oligosaccharides in infant nutrition products. Such developments in cooperation and regulatory endorsement will play a significant role in driving the industry's growth.
The market is segregated based on concentration, application, and region.
Based on concentration, the acidic HMO segment will reflect a substantial CAGR through 2032. The rising awareness of the health benefits of acidic HMO, expanding demand for specialized infant nutrition, and ongoing research demonstrating their advantages in infant health will foster growth in the segment.
The dietary supplement application segment will hold a noteworthy share of the human milk oligosaccharides market by 2032. Factors such as increasing consumer awareness of the potential health benefits of HMOs, their proven prebiotic properties, and the expanding demand for functional and nutritional supplements, particularly those targeting gut health and immune support will drive growth in the segment.
Regionally, the Asia Pacific human milk oligosaccharides (HMOs) market will grow with a commendable CAGR during the analysis period, driven by factors such as increasing birth rates, rising disposable incomes, and a growing emphasis on infant nutrition. Moreover, heightened awareness of the benefits of breastfeeding and the adoption of premium infant formula products will further drive growth in the regional industry.